ARTICLE | Clinical News
Galafold migalastat regulatory update
June 15, 2015 7:00 AM UTC
Amicus submitted an MAA to EMA for Galafold migalastat as monotherapy to treat Fabry’s disease in patients who have amenable genetic mutations. The application has accelerated assessment in the EU, wh...